Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects

Trial ID or NCT#

NCT01802073

Status

not recruiting iconNOT RECRUITING

Purpose

Determine the benefit of oral vancomycin therapy for Primary Sclerosing Cholangitis.

Official Title

Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects

Eligibility Criteria

Ages Eligible for Study: Older than 1 Year
Sexes Eligible for Study: All
Accepts Healthy Volunteers: Yes
Inclusion Criteria:
  1. - PSC Diagnosis: Liver biopsy and/or imaging (MRCP, ERCP, CT, or US - Colonoscopy within 1 year or starting of study - 2 groups: 1. IBD (Inflammatory bowel disease) and PSC: details of extent and type of IBD 2. No IBD and PSC, but positive p-ANCA or ASCA serologies indicating possible IBD.
Exclusion Criteria:
  1. - Allergy to Vancomycin - PSC not associated with IBD or NO positive IBD antibodies (p-ANCA [anti- neutrophil cytoplasmic antibody] or ASCA [anti-Saccharomyces cerevisiae antibody]) - Cholangiocarcinoma - On oral or topical (enemas or suppositories) corticosteroids,topical mesalamine, or biologics (infliximab, adalimumab, certolizumab).

Investigator(s)

Kenneth L. Cox

Contact us to find out if this trial is right for you.

Contact

Ken Cox, MD
650-721-2250